Abstract
Understanding the genetic diversity and transmission dynamics of Plasmodium falciparum, the causative agent of malaria, is crucial for effective control and elimination efforts. In some endemic regions, malaria is highly seasonal with no or little transmission during up to 8 months, yet little is known about how seasonality affects the parasite population genetics. Here we conducted a longitudinal study over 2.5 year on 1516 participants in the Upper River Region of The Gambia. With 425 P. falciparum genetic barcodes genotyped from asymptomatic infections, we developed an identity by descent (IBD) based pipeline and validated its accuracy using 199 parasite genomes. Genetic relatedness between isolates revealed a highly recombinatorial genetic diversity, suggesting continuous recombination among parasites rather than the dominance of specific strains. However, isolates from the same household were six-fold more likely to be genetically related compared to those from other villages. Seasonal patterns influenced genetic relatedness, with a notable increase of parasite differentiation during high transmission. Yet chronic infections presented exceptions, including one individual who had a continuous infection by the same parasite genotype for at least 18 months. Our findings highlight the burden of asymptomatic chronic malaria carriers and the importance of characterising the parasite genetic population at the community-level. Most importantly, ‘reactive’ approaches for malaria elimination should not be limited to acute malaria cases but be broadened to households of asymptomatic carriers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by grants from the Netherlands Organization for Scientific Research (Vidi fellowship NWO 016.158.306) and the Bill & Melinda Gates Foundation (INDIE OPP1173572), the joint MRC/LSHTM fellowship, CNRS Transversales, the French National Research Agency (ANR 18‐CE15‐0009‐01), the Fondation pour la Recherche Medicale (EQU202303016290).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Gambia Government/MRC Joint Ethics Committee (SCC 1476, SCC 1318, L2015.50) and the London School of Hygiene & Tropical Medicine Ethics Committee (Ref. 10982) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The barcode data analysis pipeline can be found at https://github.com/marcguery/gambiarcodes.
Barcode and genome metadata are in ‘Barcode_SuppTables.xlsx’.
ST1: Gender, age and households of participants.
ST2: Sampling, falciparum-malaria test results and treatment.
ST3: Locations of genotyped SNPs and their rank in barcodes.
ST4: Statistics about barcode genotyping.
ST5: Statistics about genome sequencing.
ST6: Complexity of infection metrics from barcodes.
ST7: Complexity of infection metrics from genomes.
ST8: Drug resistance markers genotyped from barcodes.
ST9: Drug resistance markers genotyped from genomes.
ST10: Duration of continuous infection estimated from barcode relatedness.
This publication uses data from the MalariaGEN SpotMalaria project as described in ‘Jacob CG et al.; Genetic surveillance in the Greater Mekong Subregion and South Asia to support malaria control and elimination; eLife 2021;10:e62997 DOI: 10.7554/eLife.62997’ [27]. The project is coordinated by the MalariaGEN Resource Centre with funding from Wellcome (206194, 090770).
